You are currently viewing Lyotropic Delivery Systems (LDS) Develops Novel Nano-Drone Drug DeliveryTechnology

Lyotropic Delivery Systems (LDS) Ltd, is a nano and biotechnology company, focused on the development of liquid nano-sized drug delivery systems for generic and innovative bio-active molecules. LDS licenses its delivery system to the specific needs of pharmaceutical, nutraceutical, and cosmetic companies to deliver a specific drug. LDS has already licensed its delivery technology to various companies in the fields, for different active compounds, including parenteral (Neoprol, propofol), ophthalmic (OphRx, various molecules) oral (Ananda Scientific, cannabinoids), Orphan drug (Golden Heart Flower, innovative molecule) and topical (Nannovate, terbinafine) and more applications.

The company has developed a proprietary patent-protected drug transport and delivery system called LDS (Lyotropic Delivery Systems) that enables the solubilization of water-insoluble and poorly permeable drug molecules, as well as biomacromolecules and enhances the drug transport across the membrane of the target cells. Its technology also creates new applications for existing generic drugs. Its portfolio of early to commercial-stage products has a range of projects with different route administrations including oral, ocular, dermal, and transdermal applications.

“With the proper transport vehicles, one can increase the drug’s efficacy and activity by directing it to target areas in the body, as well as by increasing its concentration in the formula,” explains Prof. Nissim Garti, LDS’s founder, chief scientist, and chairman.

LDS system functions like a nano drone – its ‘sense’ the target cells to which it delivers its payload of APIs (Active Pharmaceutical Ingredients).

LDS develops, under a licensing agreement, projects which are currently at both early and late stages, including R&D, pre-clinical, and clinical phases (9 ongoing clinical trials), covered by broad intellectual property rights of several platforms and numerous specific patents; some of which are granted and some under examination. LDS has the ability to give new life to an old drug, by giving it novel functionality which is patented. Thus, brand-name pharmaceutical manufacturers can delay generic competitors from entering the market by giving them enhanced delivery and controlled release, which are fully patentable.

Dr. Sharon Garti-Levi,  CEO of LDS, explains that the importance and efficacy of each drug product is not only in the active ingredient itself, but also (and sometimes mostly) in the final formulation through which it is administered, as its goal is to enable its solubility, stability, and the transportation to the target organs. “This is what our company does,” she says, emphasizing that -“the technologies developed at LDS help identify new and innovative ways to transport active ingredients, so that a large proportion of them do, indeed, make their way to their target, and more efficiently treat the disease. New formulations are almost like completely newly developed drugs. The ability to specify the drug’s transportation to the target organ is the essence of the technology we develop. It is our main advantage as a company.”

LDS’s proprietary platform technology enables the embedment of large loads of active molecules, including poorly permeable, soluble, or non-soluble active molecules solubilized on the interface of liquid nano-domains interfaces. These “flexible” nanostructures consist of lipid-based ingredients loaded with “membrane recognition”, “permeation agents”, and the active molecules, ie APIs on their interface, or core. The unique technology consists of homogeneous nanostructures with a maximum size of 50nm, forming transparent fluids. The nanostructures are non-expensive to manufacture and simple scale-up, require almost no energy input or unique equipment, and can be made at any temperature. The nano-domains are physically extremely stable, with a long shelf-life, and can be formulated to be further used as creams, tablets, sprays, films, gels, and more. Unlike solid nanoparticles that are not recommended by regulatory authorities (including the FDA and EMA) because of their involvement in cell apoptosis,LDS’s nano-domains are all liquid-based and are considered safe and non-toxic.

Dr. Sharon Garti-Levi, CEO of LDS, adds “The technology that we developed is based on liquid nanostructures that are all of the same size and unique geometry, empowering us with many advantages. First, it enables us to adapt our API to the active ingredient in any drug. Second, the liquid droplets we build simulate the natural systems found within the human body while carrying high concentrations of the active ingredient. Third, it can extend the product’s chemical and physical stability, thereby increasing its shelf life.”

LDS carefully selects the proper ingredients, all of which are considered safe and approved by the FDA, to allow each nano-domain to solubilize a specific active molecule at a required loading capacity. The nature of the active molecule and its embedding on the interface of the nano-domains (and not in their core) can be manipulated to achieve controlled release. LDS customizes the active molecule release using a few proprietary nanostructures that work together to optimize the active molecule solubility and deliverability.

How It Works

The tailor-made ‘oily’ nano-domains are designed and prepared by loading the active molecules at the interface or core of the structures. The domains are coronated with several excipients facilitating the permeation of the active molecules across surfaces, or membranes (‘permeating agents’). Only once the nano-domains migrate to the interface and recognize the delivery site will the structure adhere to the surface and allow the active molecule to be released by diffusion.

The delivery of APIs is done in four main steps:

Stages for APIs delivery by LDS system
  1. Migration of the LDS nano-domains to the membrane
    The nano-domains recognize the specific membrane surface onto which they will adhere.
  2. The LDS nano-domains adhere to the membrane of the target cell
    The nano-domains adhere to the membrane and the active molecule is released by membrane undulation.
  3. Active molecules, ie APIs, released from the LDS nano-domains  permeate the membrane and are delivered to the target cell
    The nano-domains initiate contact with the membrane allowing passive diffusion of the active molecules.
  4. The LDS nano-domains depart from the membrane

Example of the Use of the LDS System

Ananda Scientific is developing Nantheia ATL5, a CBD-based potent drug with an exceptional potential to treat problematic and even life-threatening health conditions, by using safe, non-addictive CBD-containing solutions. The problem of CBD is that it is insoluble in water (crucial for efficiently getting CBD into the body), with low bioavailability (little CBD reaches the blood-stream for transport to sites of action), with lack of absorption (most CBD taken by mouth does not enter the body) and is unstable.Ananda Scientific sublicensed LDS technology to develop an effective delivery system to turn CBD into an effective therapeutical agent.LDS delivery system is water soluble, with rapid entry into the body, and enhanced bioavailability.

The FDA recently approved the investigational new drug (IND) application for 6 clinical trials evaluating Nantheia ATL5 (Ananda Scientific), an investigational drug using cannabidiol (CBD) as an adjunctive treatment for few indications including opioid use disorder (OUD) and addiction, for the Treatment of Post-Traumatic Stress Disorder (PTSD), for the treatment of 0f Social Anxiety Disorder (SAD), based on Ananda Scientific’s Liquid Structure technology, licensed from LDS – Lyotropic Delivery Systems, which enhances the effectiveness and stability of CBD.

Two of the studies focus on creating new potential for CBD therapeutics, such as the ability to reduce opioid intake for individuals being treated for OUD and facilitating voluntary Opioid Sparing. Opioid Sparing lets a patient take a lower number of opioids and feel a similar level of pain relief while taking fewer opioids.

About Lyotropic Delivery Systems Ltd (LDS)

Lyotropic Delivery Systems Ltd (LDS) is based on the know-how and many years of research of Prof. Nissim Garti. Garti’s technology led to  LDS’s establishment in 2013, and since then has extended its expertise in the field of delivery, developing new and more advanced technologies, and strengthening the company’s IP. To date, the company has 10 ‘patent families’ that are registered in several countries around the world, 27 of which are already approved, some are under examination, and a few more are still being written. With a staff of 10 researchers, all of whom are experienced researchers with academic scientific degrees and vast experience in the industry, and external experts, LDS is engaged in several partnerships, including with some of the world’s leading pharmaceutical companies, and has its own pipeline product developments.

Address:
Hi-Tech Park | Building 5 | Unit 1, Edmond J. Safra Campus (Hebrew University)
POB 39141 Jerusalem 9139002, Israel
Contact us:
T +972-2-6308899; F +972-153-2-6561886
info AT LDS-biotech.com

Lyotropic Delivery Systems Ltd (LDS)    https://www.lds-biotech.com/

About JLM- BioCity

News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/

JLM-BioCity is a non-profit organization focused on developing and excelling in Jerusalem’s bio-community.

We invite you, researcher, professional, investor, and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.

If you want your Company featured in our blogs, or news releases, please contact: info at jlm-biocity.org